Select Page

Scientists uncover rapid-acting, low-side-effect antidepressant target

Scientists uncover rapid-acting, low-side-effect antidepressant target

Depression continues to grapple a large proportion of the population. Given the side effects associated with the long-term use of conventional antidepressants, there is a need for novel rapid acting therapeutics with minimal side effects. Researchers have previously demonstrated antidepressant-like effects of delta opioid receptor agonists in rodents. In their latest study, they uncover the molecular and cellular mechanism underlying its action that can advance its therapeutic development.

About The Author

Michael Jannicelli

Michael Jannicelli - "A PROVEN BUSINESS FIRESTARTER & BRANDING GENIUS" a true natural born Trendsetter. • Created over 100 products under 3 brands, sold in 30+ countries worldwide and influencing youth across the globe. • Featured in Forbes magazine +over 100 print publications, television talk shows, major motion pictures and national radio stations. • Co-founder and VP of Bliss beverage USA and President/co-founder of Socko International - fastest growing privately held beverage company in US (Forbes) with Hogan Energy & Raw Energy WWE. • Co-founder of Throwdown Industries (2003) - leading brand in multibillion dollar Impact/Action Sports Market (products designed for superior MN • Diagnosed with auto-immune diseases aged 13; using his experience to help others and promote a positive message while developing edgy products to benefit people with chronic illness.

Leave a reply

Your email address will not be published. Required fields are marked *